

29th July, 2022

BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Scrip Code: 500087

(3) SOCIETE DE LA BOURSE DE LUXEMBERG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Investor Presentation

Dear Sir/Madam,

 National Stock Exchange of India Ltd. Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the investor presentation dated 29th July, 2022.

This is for your information and record.

Thanking you,

Yours faithfully, For Cipla Limited

Rajendra Chopra Company Secretary

Encl: as above

Prepared by: Chirag Hotchandani

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380



Investor Presentation Q1FY23 29-7-2022

DISCLAIMER

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.


The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

Q1FY23 Performance


Sustained performance across geographies and continued momentum on core profitability





Continued focus on maintaining strong balance sheet health and robust free cash flow generation





- Robust free cash flow generation driven by prudent working capital management and optimised capex drive
- Continued governance on cash and liquidity management
- Net cash positive position continues at June-22 end reflects robust capital structure

. Total debt includes lease liabilities | 2. Includes cash and cash equivalents including fixed deposits, current investments, margin deposits and excludes unclaimed dividend balances | 3. Net Cash = Total Cash balances - Total debt

Financial Performance – Q1FY23

R&D² INR 274 Cr **1** 4% YoY



Revenues	INR 5,37	75 Cr 🛛 🖡	2% YoY
Q1 FY23 (Consolidated)			
		Actuals (INR Cr)	vs Q1 FY 22
Total Revenue from Operations		5,375	-2%
EBITDA		1,143	-15%
EBITDA % of revenue		21.3%	-318 bps
PAT		686	-4%
PAT % of revenue		12.8%	-22 bps

INR 1,143 Cr | 21.3% 🖡 15% YoY **EBITDA Revenue¹** Break-up **API**, 3% Others, 1% International. Markets, 13% SAGA,_ India, 46% 15% North America, 22%


1. India includes Rx + Gx+ CHL; SAGA includes South Africa, Sub-Saharan Africa and Cipla Global Access; International Markets include Emerging Markets and Europe | 2. Opex including depreciation | Figures have been rounded-off


Priority projects on

track

One India (Rx + Gx+ CHL¹): Continued core portfolio momentum across businesses amid significant normalisation in covid contribution

Core One-India portfolio growth tracking above 10% for most quarters; market beating growth in branded prescriptions for 5 consecutive quarters





Branded prescription business

- Sustained momentum across therapies in core portfolio driven by pricing & new introductions
- Healthy market share² and rank² across therapies

Trade generics business

- Healthy traction across our flagship brands with steady order flow across regions;
 Continued channel engagement and governance
- 16 new launches; includes anti-diabetic and ophthalmic products

Consumer health business

 Robust traction in anchor brands as well as transitioned brands

Cipla

 Sharp consumer insighting and strong onground execution

1. CHL – Cipla Health Limited 2. Market data as per IQVIA MAT June 2022 3. Trailing 12 months

Strategic product deals and investments in Q1FY23

Continued strengthening of **One-India** franchise with medium to long term growth levers



Diagnostics



Transaction description: Acquisition of **21.05% for ~INR 25 Cr.** in Achira Labs, engaged in development and commercialization of point of care (PoC) medical test kits in India

Strategic rationale: Cipla's entry in the PoC diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies; increasing patient access to innovative, affordable and quality diagnostic solutions

Wellness



Transaction description: Acquisition of Endura Mass, a renowned nutritional supplement brand in the category of weight gain from Medinn Belle Herbal Care Private Limited Strategic rationale: Expand Cipla's wellness portfolio by foraying into new category nutritional supplements for weight gain

Including Endura Mass, Domestic Consumer Business under Cipla Health expected to achieve annualized revenue of **INR 600+ Cr**

Digital




Transaction description: Acquisition of additional stake for **INR 25.9 Cr.** In GoApptiv Private Limited; Cipla's total stake increases to **22.02%** on a fully diluted basis post investment (Initial investment in June 2020)

Strategic rationale: Enable Cipla to further widen its patient reach to affordable and quality drugs with end-to-end brand marketing and channel engagement across tier 2-6 towns in India by leveraging GoApptiv's end to end digital solutions


Global consumer wellness franchise committed to provide a holistic wellness solutions; improving health outcomes





SAGA¹: South Africa, Sub-Saharan Africa and Cipla Global Access





1. Financial numbers are rounded off 2. Market data as per IQVIA MAT May 2022 | 3. Drugs for Neglected Diseases initiative

North America: Core formulation business continues steady momentum; continued serviceability across categories





10% Q1FY23 YoY growth in \$ terms

16.5%

33.4%

Steady momentum in core formulation business led by contribution from respiratory and peptide assets amongst others


Albuterol total market share¹

Arformoterol total market share¹





Q1FY23 YoY Growth in **DTM respiratory franchise**²



1. Market data as per IQVIA week ending 1st July 2022; 2. Excludes B2B revenue for the US market


North America: Respiratory, Complex generics & Peptide pipeline





ANDA¹ & NDA Portfolio & Pipeline (As on 30th June 2022)





2 PEPFAR approved ANDAs can be commercialised in US

International Markets and API






Key Business Highlights



- Strong DTM¹ growth across geographies; offset by forex volatility in emerging markets and muted B2B demand in Europe
- Steady double-digit growth in secondary terms during the quarter



Key Business Highlights



- Performance attributed to higher Q1FY22 base due to one-time profit share on an API supply
- Continued traction with global seedings & lock-ins

Our Strategic Priorities for FY23





Accelerate growth in One-India engine with sharp focus on; Building **big prescription brands across chronic therapies**, **improved productivity** and **HCP knowledge partnering**

Driving penetration and accessibility of brands for unmet chronic ailments in trade generics

Consumer insighting driving portfolio expansion to address wellness needs and purpose led brand experiences



Advancement on **innovative consumer centric products across emerging channels** to accelerate the trajectory of our Global Consumer Wellness franchise across India & South Africa



Sustainable scale up our US core formulations sales driven by high serviceability of respiratory and peptide franchise; closely monitoring upcoming high value complex launches in H2FY23



Continued execution on branded & generic portfolio, brand-building, portfolio interventions, launch excellence across DTM¹ markets



Continued cost focus, calibrated pricing actions and other interventions to navigate inflationary procurement, freight and other cost elements for insulating margins and maintaining consistent upward RoIC² trajectory



Driving value through digital adoption across businesses and functions with a dynamic agenda under Cipla Digital Health Ltd.



Focus on regulatory compliance across manufacturing facilities and implement globally benchmarked ESG³ practices

1. Direct to market | 2. Return on Invested Capital (RoIC) = EBITDA - depreciation & amortization ÷ Average [(Fixed assets including goodwill + Current assets excluding cash and cash equivalent) – Current liabilities excluding borrowing)]; Calculations based on FY22 reported EBITDA | 3. Environmental, Social, Governance

Cipla

Thank You

Registered Office :

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

For any queries, please contact Naveen Bansal Investor.Relations@cipla.com

Ankit Bhembre Investor.Relations@cipla.com

For more information please visit <u>www.cipla.com</u>